Search

Background: As the focal point of epidemic prevention and control, the mental health of COVID-19 patients cannot be ignored. Online Mindfulness-Based Stress Reduction (MBSR) allows for the provision of conveniently accessible, effective and low-cost interventions on a large scale. We aim to evaluate the effectiveness of an online MBSR intervention in alleviating anxiety and depression among asymptomatic/mild patients limited by COVID-19-related restrictions.Methods: Fifty-eight patients treated in Sanya Fangcang hospital were randomly allocated to either to the experimental group (n = 29) following daily, for 5 days, an online-based mindfulness intervention or to the control group (n = 29). Patients from both groups underwent online questionnaires including assessment of anxiety and depression status at pre- and post-tests using Self-rating Anxiety Scale and Self-Rating Depression Scale.Results: After the online-based MBSR program, the anxiety and depression scores of the patients in the MBSR group decreased significantly in comparison to the scores of those in the control group (respectively η2 = 0.175, η2 = 0.215, p < 0.001). And the proportion of severe anxiety and depression patients in the MBSR group decreased to 0% which lower than the control group, and the proportion of light anxiety and depression patients was significantly more than that in the control group after the MBSR intervention.Conclusion: The online-based MBSR intervention appears to be an effective way of alleviating anxiety and depression symptoms among COVID-19 patients with associated quarantine in Fangcang hospital. Given the seriousness of mental health threat that could be posed by this ongoing pandemic, our study provides a new idea and method for cost-effective and time-efficient interventions in the future of epidemic prevention and control. [ABSTRACT FROM AUTHOR]

In fact, DPCs are often used in several ECMO facilities.[4] Those patients with a higher risk of developing limb ischemia (eg female patients, younger patients and patients taking high doses of vasopressors) may benefit most from the prophylactic use of a DPC. In the early phases of ECMO, it has been clinically shown that the initial ischemia status of the lower extremities on the side of femoral artery cannulation naturally improves without DPC intervention.9-11 Due to their condition not rapidly improving following an ECMO procedure, some patients can progressively acquire severe limb ischemia.12-14 Therefore, it is crucial to assess whether DPC implantation is successful in treating or preventing limb ischemia in addition to its efficacy.[12],15-18 It seems that the DPC cannulation approach must be changed, and the DPC time must be adjusted. Although the use of a DPC is a widespread strategy for the prevention and treatment of limb ischemia, the number of patients with limb ischemia and its aftereffects is rising as more adult patients are obtaining femoral VA-ECMO cannulation. [Extracted from the article]

Aim: One of the most common laboratory findings in COVID-19 patients has been observed to be hypercoagulability with elevated D-dimer levels. An activation of thrombosis may be generated by hyperglycemia. We aimed to explore the association between D-dimer and in-hospital outcomes, and evaluate the synergistic effect between elevated D-dimer and hyperglycemia on COVID-19 prognosis. Methods: A retrospective cohort study was undertaken with 2467 COVID-19 inpatients. D-dimer and fasting blood glucose (FBG) on admission and adverse in-hospital outcomes (events of death and aggravated severity) were collected. Cox proportional risk model was performed to assess the association of D-dimer and adverse in-hospital outcomes, and the combined effects of D-dimer and FBG. Results: Among these COVID-19 patients, 1100 (44.6%) patients had high D-dimer (≥ 0.50 mg/L). Patients with high D-dimer were older, with higher FBG (≥ 7.00 mmol/L), and had significantly higher adjusted risk of adverse in-hospital outcomes when comparing with those who with D-dimer< 0.50 mg/L (hazard ratio, 2.73; 95% confidence interval, 1.46– 5.11). Moreover, patients with high FBG and D-dimer levels had an increasing risk (hazard ratio, 5.72; 95% confidence interval: 2.65– 12.34) than those with normal FBG and D-dimer. Conclusion: Risk of adverse in-hospital outcomes is higher among patients with high D-dimer levels. Additionally, this study found for the first time that elevated D-dimer and hyperglycemia had a synergistic effect on COVID-19 prognosis, and this risk was independent of diabetes history. [ABSTRACT FROM AUTHOR]